138 related articles for article (PubMed ID: 37452623)
1. Phase 1 safety, tolerability, pharmacokinetics and pharmacodynamic results of KCL-286, a novel retinoic acid receptor-β agonist for treatment of spinal cord injury, in male healthy participants.
Goncalves MB; Mant T; Täubel J; Clarke E; Hassanin H; Bendel D; Fok H; Posner J; Holmes J; Mander AP; Corcoran JPT
Br J Clin Pharmacol; 2023 Dec; 89(12):3573-3583. PubMed ID: 37452623
[TBL] [Abstract][Full Text] [Related]
2. Safety, tolerability and pharmacokinetics of dalcetrapib following single and multiple ascending doses in healthy subjects: a randomized, double-blind, placebo-controlled, phase I study.
Derks M; Anzures-Cabrera J; Turnbull L; Phelan M
Clin Drug Investig; 2011; 31(5):325-35. PubMed ID: 21366361
[TBL] [Abstract][Full Text] [Related]
3. Safety, Tolerability, Pharmacokinetics and Quantitative Electroencephalography Assessment of ACD856, a Novel Positive Allosteric Modulator of Trk-Receptors Following Multiple Doses in Healthy Subjects.
Önnestam K; Nilsson B; Rother M; Rein-Hedin E; Bylund J; Anderer P; Kemethofer M; Halldin MM; Sandin J; Segerdahl M
J Prev Alzheimers Dis; 2023; 10(4):778-789. PubMed ID: 37874100
[TBL] [Abstract][Full Text] [Related]
4. Safety, Tolerability, and Pharmacokinetics of Ropanicant (SUVN-911), a Novel Alpha4 Beta2 Nicotinic Acetylcholine Receptor (α4β2 nAChR) Antagonist, in Healthy Adult and Elderly Subjects.
Nirogi R; Benade V; Goyal VK; Pandey SK; Mohammed AR; Shinde A; Dogiparti D; Ravula J; Jetta S; Palacharla VRC
Clin Drug Investig; 2022 Sep; 42(9):747-762. PubMed ID: 35963959
[TBL] [Abstract][Full Text] [Related]
5. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects.
Taylor L; Gidal B; Blakey G; Tayo B; Morrison G
CNS Drugs; 2018 Nov; 32(11):1053-1067. PubMed ID: 30374683
[TBL] [Abstract][Full Text] [Related]
6. Phase I, First-in-Human, Single and Multiple Ascending Dose- and Food-Effect Studies to Assess the Safety, Tolerability and Pharmacokinetics of a Novel Anti-hepatitis B Virus Drug, Bentysrepinine (Y101), in Healthy Chinese Subjects.
Liu X; Xue L; Zhang H; Xu Q; Zhang S; Ma S; Ding X; Liu L; Dong J; Qian L; Xia W; Jiang K; Huang C; Miao L
Clin Drug Investig; 2020 Jun; 40(6):555-566. PubMed ID: 32277364
[TBL] [Abstract][Full Text] [Related]
7. A new fully human recombinant FSH (follitropin epsilon): two phase I randomized placebo and comparator-controlled pharmacokinetic and pharmacodynamic trials.
Abd-Elaziz K; Duijkers I; Stöckl L; Dietrich B; Klipping C; Eckert K; Goletz S
Hum Reprod; 2017 Aug; 32(8):1639-1647. PubMed ID: 28591833
[TBL] [Abstract][Full Text] [Related]
8. Safety and clinical pharmacokinetics of nemonoxacin, a novel non-fluorinated quinolone, in healthy Chinese volunteers following single and multiple oral doses.
Guo B; Wu X; Zhang Y; Shi Y; Yu J; Cao G; Zhang J
Clin Drug Investig; 2012 Jul; 32(7):475-86. PubMed ID: 22650326
[TBL] [Abstract][Full Text] [Related]
9. First-in-human study of CPL207280, a novel G-protein-coupled receptor 40/free fatty acid receptor 1 agonist, in healthy volunteers after single and multiple administration.
Bazydło-Guzenda K; Jarus-Dziedzic K; Gierczak-Pachulska A; Buda P; Rudzki PJ; Buś-Kwaśnik K; Juszczyk E; Tratkiewicz E; Rabczenko D; Segiet-Święcicka A; Wieczorek M
Diabetes Obes Metab; 2024 Apr; 26(4):1376-1385. PubMed ID: 38204407
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics, safety and tolerability of Bencycloquidium bromide, a novel selective muscarinic M1/M3 receptor antagonist, after single and multiple intranasal doses in healthy chinese subjects: an open-label, single-center, first-in-human study.
Sun L; Ding L; Wang Y; Zhou W; Yan Z; Sun W; Zhang H; Ou N; Chen X
Drugs R D; 2012 Mar; 12(1):17-28. PubMed ID: 22339483
[TBL] [Abstract][Full Text] [Related]
11. A Phase I, Randomized, Single‑Blind, Placebo‑Controlled, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneous and Oral TRV250, a G Protein-Selective Delta Receptor Agonist, in Healthy Subjects.
Fossler MJ; Schmith V; Greene SA; Lohmer L; Kramer MS; Arscott K; James IE; Demitrack MA
CNS Drugs; 2020 Aug; 34(8):853-865. PubMed ID: 32676977
[TBL] [Abstract][Full Text] [Related]
12. Safety, Tolerability, and Pharmacokinetic Study of 101BHG-D01 Nasal Spray, a Novel Long-Acting and Selective Cholinergic M Receptor Antagonist, in Healthy Chinese Volunteers: A Randomized, Double-Blind, Placebo-Controlled, Single-Dose Escalation, First-In-Human Study.
Chu NN; Huang K; Que LL; Ding Y; Gu XH; Zhang L; Wang JK; Chen XP; Sun ZG; He Q
Eur J Drug Metab Pharmacokinet; 2022 Jul; 47(4):509-521. PubMed ID: 35429285
[TBL] [Abstract][Full Text] [Related]
13. Safety, Pharmacokinetics, and Pharmacodynamics of the TLR4 Agonist GSK1795091 in Healthy Individuals: Results from a Randomized, Double-blind, Placebo-controlled, Ascending Dose Study.
Hug BA; Matheny CJ; Burns O; Struemper H; Wang X; Washburn ML
Clin Ther; 2020 Aug; 42(8):1519-1534.e33. PubMed ID: 32739049
[TBL] [Abstract][Full Text] [Related]
14. The Safety, Tolerability, and Pharmacokinetics Profile of BT-11, an Oral, Gut-Restricted Lanthionine Synthetase C-Like 2 Agonist Investigational New Drug for Inflammatory Bowel Disease: A Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Trial.
Leber A; Hontecillas R; Zoccoli-Rodriguez V; Colombel JF; Chauhan J; Ehrich M; Farinola N; Bassaganya-Riera J
Inflamm Bowel Dis; 2020 Mar; 26(4):643-652. PubMed ID: 31077582
[TBL] [Abstract][Full Text] [Related]
15. A phase 1, randomized study to evaluate safety, tolerability, and pharmacokinetics of GDC-3280, a potential novel anti-fibrotic small molecule, in healthy subjects.
Cheung D; Fong A; Ding HT; Cabanski CR; Wang J; Chen Y; Bush J; Harris JM; Pan L
Pulm Pharmacol Ther; 2021 Aug; 69():102051. PubMed ID: 34166834
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics, Safety, and Tolerability of Single Oral Doses of a Novel Oxytocin Receptor Antagonist-Cligosiban-in Development for Premature Ejaculation: Three Randomized Clinical Trials in Healthy Subjects.
Osterloh IH; Muirhead GJ; Sultana S; Whaley S; van den Berg F; Atiee G
J Sex Med; 2018 Nov; 15(11):1547-1557. PubMed ID: 30341006
[TBL] [Abstract][Full Text] [Related]
17. Safety, pharmacokinetics and pharmacodynamics of HRS-7535, a novel oral small molecule glucagon-like peptide-1 receptor agonist, in healthy participants: A phase 1, randomized, double-blind, placebo-controlled, single- and multiple-ascending dose, and food effect trial.
Wu J; Zhou R; Zhang Q; Zhang Q; Qin H; Ye Z; Xu Y; Feng S; Shu C; Shen Y; Fan Y; Wang Q; Du Y; Hu W
Diabetes Obes Metab; 2024 Mar; 26(3):901-910. PubMed ID: 38100147
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics, Safety Profile, and Tolerability of Tetramethylpyrazine Nitrone Tablets After Single and Multiple Ascending Doses in Healthy Chinese Volunteers.
Zhu G; Wang L; Zhong S; Han S; Peng H; Tong M; He X
Eur J Drug Metab Pharmacokinet; 2024 Mar; 49(2):207-217. PubMed ID: 38381348
[TBL] [Abstract][Full Text] [Related]
19. Single- and multiple-dose safety, tolerability, pharmacokinetic, and pharmacodynamic profiles of ASP0367, or bocidelpar sulfate, a novel modulator of peroxisome proliferator-activated receptor delta in healthy adults: Results from a phase 1 study.
Ito M; Tauscher-Wisniewski S; Smulders RA; Wojtkowski T; Yamada A; Koibuchi A; Uz T; Marek GJ; Goldwater RD
Muscle Nerve; 2022 Jan; 65(1):110-120. PubMed ID: 34642949
[TBL] [Abstract][Full Text] [Related]
20. Safety, tolerability and pharmacokinetics of GSK3008348, a novel integrin αvβ6 inhibitor, in healthy participants.
Maden CH; Fairman D; Chalker M; Costa MJ; Fahy WA; Garman N; Lukey PT; Mant T; Parry S; Simpson JK; Slack RJ; Kendrick S; Marshall RP
Eur J Clin Pharmacol; 2018 Jun; 74(6):701-709. PubMed ID: 29532104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
